(Reuters) – Johnson & Johnson’s manufacturing partner Emergent Biosolutions said on Thursday that it had disposed off the single batch of COVID-19 drug substance that did not meet specifications.
J&J on Wednesday said it had found a problem with a batch of the drug substance for its COVID-19 vaccine being produced at Emergent’s site in Baltimore, Maryland.
“Discarding a batch of bulk drug substance, while disappointing, does occasionally happen during vaccine manufacturing, which is a complex and multi-step biological process”, Emergent said.
(Reporting by Dania Nadeem in Bengaluru; Editing by Anil D’Silva)
